MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/alz.70062

Медицинская библиотека · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction.

Wang Hong, Serap Monkul Nery Emel, Ardayfio Paul, Khanna Rashna, Otero Svaldi Diana, Gueorguieva Ivelina, Shcherbinin Sergey, Andersen Scott W, Hauck Paula M, Engle Staci E, Brooks Dawn A, Collins Emily C, Fox Nick C, Greenberg Steven M, Salloway Stephen, Mintun Mark A, Sims John R

СтатьяРандомизированное исследованиеМногоцентровое исследованиеКлиническое исследование III фазыПеревод в очереди

Аннотация

INTRODUCTION

TRAILBLAZER-ALZ 6 (NCT05738486) is a multicenter, double-blind, ongoing phase 3b study in early symptomatic Alzheimer's disease.

METHODS

Participants (n = 843) were randomized 1:1:1:1 (standard + three alternative donanemab dosing arms). Primary outcome was relative risk reduction (RRR) of amyloid-related imaging abnormalities with edema/effusions (ARIA-E) at 24 weeks assessed with Bayesian logistic regression. Amyloid plaque levels by positron emission tomography and serum donanemab pharmacokinetics were measured.

RESULTS

ARIA-E frequencies for standard, modified titration, dose skipping, and Cmax arms were 23.7%, 13.7%, 18.6%, and 18.3%, respectively, at 24 weeks and similar at 52 weeks: 24.2%, 15.6%, 18.6%, and 18.8%, respectively. Modified titration met the 24-week primary outcome with 94% probability of achieving ≥ 20% RRR versus the standard arm. Modified titration also had significantly lower ARIA-E severity, but similar cumulative exposure and mean amyloid reduction compared to the standard arm.

DISCUSSION: Gradual up-titration of dose significantly reduced ARIA-E risk while demonstrating comparable pharmacokinetics/pharmacodynamics compared to standard dosing.

HIGHLIGHTS: In TRAILBLAZER-ALZ 6, the amyloid-related imaging abnormalities-edema/effusions (ARIA-E) frequency was 13.7% in the modified titration arm compared to 23.7% in the standard arm at week 24. The modified titration arm met the primary endpoint of ARIA-E relative risk reduction at 24 weeks versus the standard arm. The modified titration versus standard arm at week 24 had comparable non-ARIA-E related safety profile, amyloid reduction, plasma phosphorylated tau217 reduction, cumulative exposure, and pharmacokinetics. Data at week 52 were consistent with week 24 results.

Для цитирования: Wang Hong, Serap Monkul Nery Emel, Ardayfio Paul, Khanna Rashna, Otero Svaldi Diana, Gueorguieva Ivelina, Shcherbinin Sergey, Andersen Scott W, Hauck Paula M, Engle Staci E, Brooks Dawn A, Collins Emily C, Fox Nick C, Greenberg Steven M, Salloway Stephen, Mintun Mark A, Sims John R. Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. DOI: 10.1002/alz.70062.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.